US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5
By A Mystery Man Writer
Description
![US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5](https://article.imrpress.com/journal/FBL/28/9/10.31083/j.fbl2809209/2768-6698-28-9-209/fig1.jpg)
CD5L Deficiency Protects Mice Against Bleomycin-Induced Pulmonary
![US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5](https://cdn.antibodies.com/image/logo.png)
Anti-CD95/FAS (phospho-Y291) Antibody (A29570)
![US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5](https://ars.els-cdn.com/content/image/1-s2.0-S2211383520305426-fx1.jpg)
Efficient drug and gene delivery to liver fibrosis: rationale
Mouse Monoclonal Anti-CD45 Antibody (MEM-28). Tested Applications: Western Blot, Flow Cytometry, ICC, IHC, IHC-Paraffin, IP. Tested Reactivity: Human.
![US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5](https://images.novusbio.com/images/CD45-Antibody-MEM-28-Flow-Cytometry-NB500-319-img0016.jpg)
CD45 Antibody (MEM-28) - BSA Free (NB500-319): Novus Biologicals
Mouse Monoclonal Anti-CD45 Antibody (MEM-28). Tested Applications: Western Blot, Flow Cytometry, ICC, IHC, IHC-Paraffin, IP. Tested Reactivity: Human.
![US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5](https://images.novusbio.com/images/CD45-Antibody-MEM-28-Flow-Cytometry-NB500-319-img0020.jpg)
CD45 Antibody (MEM-28) - BSA Free
![US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5](https://img.patentguru.com/US/2023/1207/US20230393133A1/US20230393133A1-20231207-D00001.TIF_210x210.png)
University of pennsylvaniaPatents
![US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fsrep23314/MediaObjects/41598_2016_Article_BFsrep23314_Fig1_HTML.jpg)
In vivo imaging of prostate cancer using an anti-PSMA scFv
![US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5](https://www.ptglab.com/products/pictures/His-Tag-Antibody-66005-1-Ig-IF-151867.jpg)
6*His, His-Tag antibody (66005-1-Ig)
![US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5](https://assets.fishersci.com/TFS-Assets/CCG/product-images/F774808.jpg-650.jpg)
CEACAM5/CD66e Antibody (CB30), DyLight 488, Novus Biologicals 100
![US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5](https://patentimages.storage.googleapis.com/98/69/43/47f4b9e107d779/imgf000065_0001.png)
WO2015183842A1 - Methods and compositions for preventing ischemia
![US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5](https://ars.els-cdn.com/content/image/1-s2.0-S0169409X17301072-gr1.jpg)
Drug targeting to myofibroblasts: Implications for fibrosis and
![US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5](https://cdn.antibodies.com/image/catalog/29/A29570_1.jpg?profile=product_top)
Anti-CD95/FAS (phospho-Y291) Antibody (A29570)
![US20230203538A1 - In vivo targeting of Fibrosis by anti-CD5](https://www.researchgate.net/publication/321512240/figure/fig3/AS:571282279809025@1513215717398/GDF15-deficiency-exacerbates-CCl-4-induced-liver-fibrosis-a-Serum-levels-of-AST-and.png)
GDF15 deficiency exacerbates CCl 4-induced liver fibrosis. (a
from
per adult (price varies by group size)